14 Total results for product and free and sample content found
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
New clinical data and a deepening treatment algorithm will drive market growth
Topic research-wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica.
Topic research-wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.
Topic research-wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.
Topic Research wire Alzheimers
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.
Topic research-wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.
Topic research-wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.
Topic Research wire
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.
Topic research-wire
No Records Found
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
